MedTrace Logo

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

NCT03057145 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-09-02

No results posted yet for this study

Summary

This research study is studying a combination of targeted therapies as a possible treatment for Advanced Solid Tumors.

The study interventions involved in this study are:

* LY2606368
* Olaparib

Conditions

Interventions

DRUG

Prexasertib

LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer

DRUG

Olaparib

Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.

Sponsors & Collaborators

Principal Investigators

  • Geoffrey Shapiro, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-10
Primary Completion
2020-02-25
Completion
2021-06-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03057145 on ClinicalTrials.gov